A therapeutic strategy for choroidal neovascularization based on recruitment of mesenchymal stem cells to the sites of lesions

Molecular Therapy

Volumn 18, Issue 10, 2010, Pages 1837-1845

  Hou, Hui Yuan ^a   Liang, Hong Liang ^a   Wang, Yu Sheng ^a   Zhang, Zhao Xia ^a   Wang, Bai Ren ^b   Shi, Yuan Yuan ^a   Dong, Xiao ^a   Cai, Yan ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PIGMENT EPITHELIUM DERIVED FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL ACTIVITY; CELL BASED GENE THERAPY; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE DELIVERY SYSTEM; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; PIGMENT EPITHELIUM; SUBRETINAL NEOVASCULARIZATION;

EID: 77957597705     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.144     Document Type: Article

References (45)

1. Tong, JP and Yao, YF (2006). Contribution of VEGF and PEDF to choroidal angiogenesis: a need for balanced expressions. Clin Biochem 39: 267-276.
2. Grossniklaus, HE and Green, WR (2004). Choroidal neovascularization. Am J Ophthalmol 137: 496-503.
3. No?l, A, Jost, M, Lambert, V, Lecomte, J and Rakic, JM (2007). Anti-angiogenic therapy of exudative age-related macular degeneration: current progress and emerging concepts. Trends Mol Med 13: 345-352.
4. Ambati, J, Ambati, BK, Yoo, SH, Ianchulev, S and Adamis, AP (2003). Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 48: 257-293.
5. Afzal, A, Shaw, LC, Ljubimov, AV, Boulton, ME, Segal, MS and Grant, MB (2007). Retinal and choroidal microangiopathies: therapeutic opportunities. Microvasc Res 74: 131-144.
6. Ball, SG, Shuttleworth, CA and Kielty, CM (2007). Mesenchymal stem cells and neovascularization: role of platelet-derived growth factor receptors. J Cell Mol Med 11: 1012-1030.
7. Ghajar, CM, Blevins, KS, Hughes, CC, George, SC and Putnam, AJ (2006). Mesenchymal stem cells enhance angiogenesis in mechanically viable prevascularized tissues via early matrix metalloproteinase upregulation. Tissue Eng 12: 2875-2888.
8. Liu, K, Chi, L, Guo, L, Liu, X, Luo, C, Zhang, S et al. (2008). The interactions between brain microvascular endothelial cells and mesenchymal stem cells under hypoxic conditions. Microvasc Res 75: 59-67.
9. Oh, JY, Kim, MK, Shin, MS, Lee, HJ, Ko, JH, Wee, WR et al. (2008). The antiinflammatory and anti-angiogenic role of mesenchymal stem cells in corneal wound healing following chemical injury. Stem Cells 26: 1047-1055.
10. Studeny, M, Marini, FC, Champlin, RE, Zompetta, C, Fidler, IJ and Andreeff, M (2002). Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 62: 3603-3608.
11. Ozawa, K, Sato, K, Oh, I, Ozaki, K, Uchibori, R, Obara, Y et al. (2008). Cell and gene therapy using mesenchymal stem cells (MSCs). J Autoimmun 30: 121-127.
12. Studeny, M, Marini, FC, Dembinski, JL, Zompetta, C, Cabreira-Hansen, M, Bekele, BN et al. (2004). Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 96: 1593-1603.
13. Mohr, A, Lyons, M, Deedigan, L, Harte, T, Shaw, G, Howard, L et al. (2008). Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model. J Cell Mol Med 12: 2628-2643.
14. Hall, B, Andreeff, M and Marini, F (2007). The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles. Handb Exp Pharmacol (180): 263-283.
15. Kyriakou, CA, Yong, KL, Benjamin, R, Pizzey, A, Dogan, A, Singh, N et al. (2006). Human mesenchymal stem cells (hMSCs) expressing truncated soluble vascular endothelial growth factor receptor (tsFlk-1) following lentiviral-mediated gene transfer inhibit growth of Burkitt's lymphoma in a murine model. J Gene Med 8: 253-264.
16. Tomita, M, Yamada, H, Adachi, Y, Cui, Y, Yamada, E, Higuchi, A et al. (2004). Choroidal neovascularization is provided by bone marrow cells. Stem Cells 22: 21-26.
17. Sengupta, N, Caballero, S, Mames, RN, Butler, JM, Scott, EW and Grant, MB (2003). The role of adult bone marrow-derived stem cells in choroidal neovascularization. Invest Ophthalmol Vis Sci 44: 4908-4913. (Pubitemid 37315308)
18. Espinosa-Heidmann, DG, Caicedo, A, Hernandez, EP, Csaky, KG and Cousins, SW (2003). Bone marrow-derived progenitor cells contribute to experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 44: 4914-4919.
19. Takahashi, H, Yanagi, Y, Tamaki, Y, Muranaka, K, Usui, T and Sata, M (2004). Contribution of bone-marrow-derived cells to choroidal neovascularization. Biochem Biophys Res Commun 320: 372-375.
20. Espinosa-Heidmann, DG, Reinoso, MA, Pina, Y, Csaky, KG, Caicedo, A and Cousins, SW (2005). Quantitative enumeration of vascular smooth muscle cells and endothelial cells derived from bone marrow precursors in experimental choroidal neovascularization. Exp Eye Res 80: 369-378.
21. Mori, K, Gehlbach, P, Yamamoto, S, Duh, E, Zack, DJ, Li, Q et al. (2002). AAVmediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci 43: 1994-2000.
22. Mori, K, Gehlbach, P, Ando, A, McVey, D, Wei, L and Campochiaro, PA (2002). Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 43: 2428-2434.
23. Spaide, RF (2006). Rationale for combination therapies for choroidal neovascularization. Am J Ophthalmol 141: 149-156.
24. Kent, D and Sheridan, C (2003). Choroidal neovascularization: a wound healing perspective. Mol Vis 9: 747-755.
25. Lima e Silva, R, Shen, J, Hackett, SF, Kachi, S, Akiyama, H, Kiuchi, K et al. (2007). The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularization. FASEB J 21: 3219-3230. (Pubitemid 47565540)
26. Okuyama, H, Krishnamachary, B, Zhou, YF, Nagasawa, H, Bosch-Marce, M and Semenza, GL (2006). Expression of vascular endothelial growth factor receptor 1 in bone marrow-derived mesenchymal cells is dependent on hypoxia-inducible factor 1. J Biol Chem 281: 15554-15563.
27. Csaky, KG, Baffi, JZ, Byrnes, GA, Wolfe, JD, Hilmer, SC, Flippin, J et al. (2004). Recruitment of marrow-derived endothelial cells to experimental choroidal neovascularization by local expression of vascular endothelial growth factor. Exp Eye Res 78: 1107-1116.
28. Docheva, D, Popov, C, Mutschler, W and Schieker, M (2007). Human mesenchymal stem cells in contact with their environment: surface characteristics and the integrin system. J Cell Mol Med 11: 21-38.
29. Hall, B, Dembinski, J, Sasser, AK, Studeny, M, Andreeff, M and Marini, F (2007). Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles. Int J Hematol 86: 8-16.
30. Bhutto, IA, McLeod, DS, Hasegawa, T, Kim, SY, Merges, C, Tong, P et al. (2006). Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Exp Eye Res 82: 99-110.
31. Sarojini, H, Estrada, R, Lu, H, Dekova, S, Lee, MJ, Gray, RD et al. (2008). PEDF from mouse mesenchymal stem cell secretome attracts fibroblasts. J Cell Biochem 104: 1793-1802.
32. Zhang, SX, Wang, JJ, Gao, G, Parke, K and Ma, JX (2006). Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. J Mol Endocrinol 37: 1-12.
33. Apte, RS, Barreiro, RA, Duh, E, Volpert, O and Ferguson, TA (2004). Stimulation of neovascularization by the anti-angiogenic factor PEDF. Invest Ophthalmol Vis Sci 45: 4491-4497.
34. Becerra, SP (2006). Focus on molecules: pigment epithelium-derived factor (PEDF). Exp Eye Res 82: 739-740.
35. Barnstable, CJ and Tombran-Tink, J (2004). Neuroprotective and antiangiogenic actions of PEDF in the eye: molecular targets and therapeutic potential. Prog Retin Eye Res 23: 561-577.
36. Notari, L, Baladron, V, Aroca-Aguilar, JD, Balko, N, Heredia, R, Meyer, C et al. (2006). Identification of a lipase-linked cell membrane receptor for pigment epitheliumderived factor. J Biol Chem 281: 38022-38037.
37. Becerra, SP, Fariss, RN, Wu, YQ, Montuenga, LM, Wong, P and Pfeffer, BA (2004). Pigment epithelium-derived factor in the monkey retinal pigment epithelium and interphotoreceptor matrix: apical secretion and distribution. Exp Eye Res 78: 223-234.
38. Grisanti, S and Tatar, O (2008). The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res 27: 372-390.
39. Prockop, DJ (1997). Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276: 71-74.
40. Pittenger, MF, Mackay, AM, Beck, SC, Jaiswal, RK, Douglas, R, Mosca, JD et al. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-147.
41. Breitbach, M, Bostani, T, Roell, W, Xia, Y, Dewald, O, Nygren, JM et al. (2007). Potential risks of bone marrow cell transplantation into infarcted hearts. Blood 110: 1362-1369.
42. Hou, HY, Wang, YS, Xu, JF, Wang, YC and Liu, JP (2006). The dynamic conduct of bone marrow-derived cells in the choroidal neovascularization microenvironment. Curr Eye Res 31: 1051-1061.
43. Hou, HY, Wang, YS, Xu, JF and Wang, BR (2008). Nicotine promotes contribution of bone marrow-derived cells to experimental choroidal neovascularization in mice. Exp Eye Res 86: 983-990.
44. Mori, K, Duh, E, Gehlbach, P, Ando, A, Takahashi, K, Pearlman, J et al. (2001). Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol 188: 253-263.
45. Wang, YS, Hui, YN and Wiedemann, P (2002). Role of apoptosis in the cytotoxic effect mediated by daunorubicin in cultured human retinal pigment epithelial cells. J Ocul Pharmacol Ther 18: 377-387.